Ascelia Pharma AB (SE:ACE)
:ACE
Want to see SE:ACE full AI Analyst Report?
ACE Stock Chart & Stats
kr3.17
-kr0.11(-3.47%)
At close: 4:00 PM EST
kr3.17
-kr0.11(-3.47%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr5.23
Previous CloseN/A
Volume171.87K
Average Volume (3M)1.75M
Market Cap
kr366.65M
Enterprise Valuekr334.72M
Total Cash (Recent Filing)kr33.89M
Total Debt (Recent Filing)kr689.00K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding126,868,800
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)kr87.22M
Bulls Say, Bears Say
Bulls Say
Differentiated Lead Product (Orviglance)Orviglance targets a specific clinical niche—MRI liver imaging for patients unsuitable for gadolinium—creating a structural product differentiation. If clinical and regulatory milestones are met, this focused indication supports durable commercial and partnership potential versus broad undifferentiated contrast agents.
Low Financial LeverageVery low leverage reduces fixed financial obligations and bankruptcy risk, giving management flexibility to pursue R&D, partnerships, or staged commercialization. This structural balance-sheet strength lengthens runway options and lowers interest burden versus highly leveraged peers.
Improving Cash Burn TrendA materially improved burn rate versus prior years indicates progress in cost control or program sequencing. While cash flow remains negative, a sustained reduction in burn is a durable operational improvement that lowers near-term financing pressure and extends time to reach development inflection points.
Bears Say
No Revenue; Persistent Net LossesAbsence of commercial revenue and large recurring net losses are structural constraints for a development-stage biotech. Continued losses deplete equity, force external financing, and mean profitability is unlikely until product approval and commercialization, limiting long-term self-funding ability.
Weak Cash Generation; Sizable Ongoing BurnPersistently negative operating and free cash flow requires steady access to capital markets or partners. The sizable TTM outflows create structural refinancing risk and potential dilution, constraining the company’s ability to independently fund late-stage trials or build commercial capabilities.
Eroding Equity And Asset BaseDeclining equity and assets reflect balance-sheet consumption from ongoing losses. This structural erosion reduces borrowing capacity and strategic flexibility, making future financing more urgent and potentially more costly if losses persist through upcoming development cycles.
Ascelia Pharma AB News
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr2.53 and its highest was kr5.23 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr366.65M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 90 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 12, 2026. The company reported -kr0.129 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.129.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 126,868,800 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.129 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.372%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―